Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs prolong the action potential primarily by blocking potassium channels, which delays repolarization. Some agents also block inactivated sodium channels to enhance inward currents. This prolongation increases the refractory period without affecting the resting membrane potential, effectively reducing sinus rate and AV conduction while raising the fibrillation threshold.

Reverse use dependence is a unique property of Class III drugs where their effects are most pronounced at slower heart rates. This characteristic increases the risk of torsades de pointes, a dangerous arrhythmia. Unlike typical use-dependent drugs that work better at faster rates, Class III agents paradoxically become more potent when the heart beats slowly, complicating their clinical safety profile.

Amiodarone contains iodine and has a very long half-life, leading to accumulation and multiple adverse effects. These include pulmonary fibrosis, optic neuritis, thyrotoxicity, liver damage, skin discoloration, and corneal microdeposits. Its structural similarity to thyroxine contributes to thyroid dysfunction, making careful monitoring essential during long-term therapy for severe ventricular and supraventricular arrhythmias.

Dronedarone is a shorter half-life analog of amiodarone that lacks iodine, significantly reducing thyroid-related toxicity. It blocks multiple channels including potassium and calcium channels, and must be taken with food for optimal absorption. These modifications lower overall toxicity while maintaining antiarrhythmic efficacy for managing atrial fibrillation and maintaining sinus rhythm.

Sotalol is a racemic mixture with dual properties: its L-isomer provides beta-blocking activity while the entire molecule exhibits Class III potassium channel blocking effects. This combination allows it to treat life-threatening ventricular arrhythmias and maintain sinus rhythm. However, it carries risks of torsades de pointes and can worsen heart failure, requiring careful patient selection and monitoring.

Dofetilide and ibutilide are administered only under medical supervision because they carry substantial proarrhythmic risks from QT interval prolongation and torsades de pointes. Dofetilide blocks the rapid potassium current and requires baseline kidney function assessment since it is eliminated unchanged by the kidneys. Ibutilide, rapidly cleared by liver and kidneys, can cause excessive QT prolongation, necessitating continuous cardiac monitoring during initiation.

While QT interval prolongation is commonly monitored, it is not always the best predictor of torsades de pointes. Action potential stability, triangulation, reverse use dependence, and repolarization time dispersion are equally important factors. These parameters reflect the underlying electrophysiological mechanisms that Class III drugs disrupt, making comprehensive assessment necessary for predicting arrhythmia risk in individual patients.